A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: absent (23), missing (300), gone (960)

Annual ward staffing review January 2025

Description
[5.15] Report to the Trust Board of Directors, 7th January 2025 Title: Ward Staffing Nursing Establishment Review July 2024 – October 2024
Url
/Media/UHS-website-2019/Docs/About-the-Trust/performance/TB-6-monthly-staffing-review-report.pdf

Records management policy

Description
Records Management Policy Date Issued: Review Date: Document Type: 9 May 2018 19 April 2021 Policy Version: 6 Contents Paragraph 1
Url
/Media/UHS-website-2019/Docs/Policies/Records-management-policy.pdf

DH IVIg approved indications full guidance July 2011

Description
DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Targ
Url
/Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory/relapsed euroblastoma Version
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • D
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Nivolumab ver 1 (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastat
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

Nivolumab 240mg (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

Nivolumab 480mg (renal)

Description
Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

Nivolumab 240mg (renal)

Description
Chemotherapy Protocol RENAL CELL CANCER Nivolumab (240mg-14 days) Regimen • Renal Cell – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-240mg.pdf
51 to 60 of 413
Previous … 4 5 6 7 8 … Next